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S
plevated blood pressure (BP) is one of the most common
reventable causes of premature death worldwide. Approxi-
ately 8 million deaths/year (i.e., 14% of all deaths worldwide)
re directly attributable to an elevated BP, and with the
orldwide prevalence of hypertension predicted to increase by
ore than 50% by 2025, the magnitude of BP-related death is
et to increase further (1). Abundant data from randomized
linical trials have confirmed that the therapeutic lowering of
P in hypertensive people substantially reduces the risk of
ardiovascular morbidity and mortality, and as a consequence,
he routine treatment of hypertension is one of the most
ommon interventions in medicine. BP treatment guidelines
ave progressively reduced the BP threshold at which treat-
ent should begin and the BP target to which BP should be
owered. This has led to a legitimate debate as to how low BP
an safely be lowered to achieve optimal benefit from treatment
nd concern from some that the therapeutic “harm/benefit”
quation might shift toward harm in some patients in whom
P is lowered too much. Over many years, this concern has
ueled a seemingly eternal “J-curve” debate about the safety of
hat some deem to be excessive BP lowering (2–4). The
J-curve” describes the shape of the relationship between BP
nd the risk of cardiovascular morbidity and/or mortality. The
shape reflects increased risk at high levels of BP, with risk
alling in parallel to BP reduction until a nadir is reached,
elow which further BP reduction begins to increase risk. That
here is a J-curve relationship between the level of BP and risk
s not in doubt, because there must come a point at which BP
ecomes too low to sustain adequate perfusion to vital organs
nd life itself. Thus, the essence of the debate is whether this
-curve exists in the range of BP at which patients might be
xposed to further BP lowering by treatment. How low can BP
e lowered and remain both safe and beneficial? What is the
ower level of BP at which potential harm offsets the benefit of
reatment? Other important aspects of this debate are whether
he J-curve relationship is more significant for systolic blood
ressure (SBP) or diastolic blood pressure (DBP) and whether
ts impact is more relevant for specific clinical outcomes and in
atients with different comorbidities, especially coronary heart
isease.
rom the Department of Cardiovascular Sciences and the NIHR Cardiovascular
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Manuscript received May 29, 2009, accepted June 2, 2009.In this issue of the Journal, Messerli and Panjrath (5) add
uel to the J-curve fire by using post hoc analyses of clinical
rials to examine the association between in-trial SBP and
BP and various clinical cardiovascular end points. They
onclude that a J-curve exists for DBP for patients with
oronary artery disease (CAD) but were not convinced that
here was a J-curve phenomenon with BP-lowering therapy for
enal disease or stroke prevention (5). They reason that patients
ith CAD might be especially vulnerable to risk from a low
BP because the coronary circulation is critically dependent on
erfusion during diastole and requires an adequate pressure.
he data as presented seem compelling and are persuasively
rgued—but are they right?
This is a hugely important clinical dilemma, worthy of closer
nspection and debate, not least of all because these analyses
reate the impression that therapeutic lowering of DBP, within
range frequently encountered in routine clinical practice,
ould be harmful to many millions of treated patients. I would
dd a note of caution before accepting this as fact. There is
uge potential for confounding in this kind of analysis that I
ear cannot be overcome by any amount of multivariate
tatistical adjustment. Modern medicine struggles to reverse
he powerful impact of aging and comorbidities on cardiovas-
ular disease risk, and yet we accept that statistical adjustment
an do so at a stroke?
It is most important to recognize that data showing associ-
tions between low in-trial DBP and risk do not prove that the
herapeutic lowering of DBP caused that risk. On the contrary,
t is most likely that patients with low in-trial DBP in the
arious studies cited had a low DBP at baseline, at entry into
he study. Moreover, a low baseline DBP would automatically
dentify a cohort of patients at high cardiovascular disease risk.
uch patients are more likely to experience clinical events in the
rials not necessarily because lowering of their DBP has caused
he events but rather because a low baseline DBP predicts their
vents. This latter point is important because a lowDBP tracks
ith a number of confounders.
DBP tends to decline with age, from approximately the age
f 40 to 50 years, due to progressive stiffening and loss of
ompliance of large conduit arteries, especially the aorta. This
ortic stiffening tends to be accelerated in people with diabetes
6). The same mechanism accounts for the progressive rise in
BP with age and the consequent age-related increase in pulse
ressure (7). Thus, the cohort of patients with low in-trial
BP are most likely to be older and have diabetes and more
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Hypertension and the J-Curve November 10, 2009:1835–6ikely to have coronary heart disease and a higher SBP and
ulse pressure. Therefore, they are the highest-risk cohort
rrespective of subsequent treatment. Indeed, a review of the
atient characteristics in a recent analysis of the J-curve
henomenon from a major clinical outcomes study of hyper-
ensive patients clearly shows that those patients with a low
n-trial DBP had baseline characteristics identical to those
escribed in the preceding text—therefore, they were, not
urprisingly, at higher risk of developing incident coronary
vents during the trial (8). The cohort of patients with low
BP at baseline would most likely have experienced the
ighest rate of cardiac events irrespective of whether their DBP
as lowered further. This in turn highlights the key question in
his debate: if a patient already has a low DBP, will they get
enefit or harm from further DBP lowering? Whilst reflecting
n this question, it is worth remembering that patients with a
ow DBP will also most likely be those with a high SBP and
ulse pressure. Put simply, would you lower the BP of a patient
ith isolated systolic hypertension (ISH), (e.g., a BP of 180/70
m Hg)? Current guidelines recommend that you should.
hould this recommendation hold true if the patient also has
vidence of coronary disease due to concerns about the impact
f further DBP lowering?With regard to the latter, in patients
ith ISH, the fall in SBP will greatly exceed the fall in DBP.
ndeed, with aging, the predominant effect of treatment is to
ower SBP, because the ratio of DBP/SBP lowering with
ntihypertensive therapy progressively declines with age and
ow baseline DBP (9). This underscores the likelihood that the
ow in-trial DBP analyzed in the aforementioned analyses (5,8)
lmost certainly reflects a low baseline DBP rather than a
ramatic treatment effect.
The question as to whether patients with ISH should have
heir BP lowered even if their DBP is already low cannot be
ddressed by post hoc analyses of the association between
n-trial DBP and clinical outcomes without reference to the
aseline DBP, because of the aforementioned confounding.
his question has been addressed, however, by a number of
andomized clinical trials of patients with ISH that have
verwhelmingly demonstrated the strong net benefits of BP
owering. In this regard, Wang et al. (9) performed a quanti-
ative overview of trials that tested active antihypertensive
rugs against placebo or no treatment in thousands of patients
cross a spectrum of age and baseline DBP. Crucially, with
ndividual patient data, they also conducted a matched pair
nalysis to match patients for their baseline BP and other
haracteristics, and then compared active treatment with pla-
ebo. Antihypertensive treatment reduced the risk of all car-
iovascular events, stroke, and myocardial infarction across all
ge and BP strata to a similar extent, and the absolute benefit
f treatment increased with age (i.e., in those with the lowest
BP). Moreover, in patients with a larger-than-median re-
uction in SBP, active treatment consistently reduced the risk
f all outcomes irrespective of the associated decrease in DBP
r the achieved DBP. These findings remained consistent even
f the achieved DBP averaged 70 mm Hg (9). Thus, the
K
panger of advocating a J-curve for DBP on the basis of
otentially confounded observational in-trial data is that it risks
ndermining the treatment of those with a high SBP (i.e.,
hose at highest absolute risk of events and with the greatest
bsolute benefit from treatment) (10). Moreover, as discussed
arlier, those with ISH experience the smallest fall in DBP
elative to the change in SBP with treatment.
Since the aforementioned analysis by Wang et al. (9), there
ave been further patients with low baseline DBP entered into
andomized clinical trials of BP-lowering therapy. What is
learly needed are extensive individual patient data analyses of
hose with a low baseline DBP who have been randomized to
ctive BP-lowering treatment or placebo to determine whether
he high baseline risk of these patients is modified by treat-
ent, either in a positive or negative direction. This is the only
ay to comprehensively address the J-curve question and
efine the safety of treatment for patients with a low DBP,
specially those with established CAD. Clearly, there is a point
t which both DBP and SBP become too low to sustain life.
he challenge is to better define the limits of intervention and
hether there are groups of people who are particularly
usceptible to over-aggressive lowering of BP. In the mean-
ime, while post hoc association studies can generate interest-
ng hypotheses and debate, they must never be used to frame
reatment recommendations or, worse, alarm physicians into
nder-treating patients with ISH.
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